Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes

This study has been terminated.
(See termination reason in detailed description.)
Sponsor:
Information provided by:
Pfizer
ClinicalTrials.gov Identifier:
NCT00136916
First received: August 25, 2005
Last updated: February 12, 2010
Last verified: December 2009
  Purpose

This study is being done to find out the good and bad effects of inhaled insulin that is used by oral inhalation, to adult males and females with type 2 diabetes mellitus. The other name for this inhaled insulin is Exubera®.

This study included a 2-year comparative treatment period followed by a 6-month follow-up period during which inhaled insulin-treated subjects were switched back to subcutaneous short-acting insulin. After this follow-up period, all eligible subjects entered a comparative extension period that was to last for 5 years. When the comparative portion of the study was terminated, all subjects were requested to return for a final extension follow-up month 3 visit.


Condition Intervention Phase
Diabetes Mellitus
Drug: Inhaled Insulin
Drug: Subcutaneous insulin
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Exubera® (Inhaled Insulin) Compared With Subcutaneous Human Insulin Therapy in Adult Subjects With Type 2 Diabetes Mellitus: A Long-Term, Outpatient, Open-Label, Parallel-Group Comparative Trial

Resource links provided by NLM:


Further study details as provided by Pfizer:

Primary Outcome Measures:
  • Change From Month 3 in Forced Expiratory Volume in 1 Second (FEV1) [ Time Frame: Month 3 through extension Month 60 ] [ Designated as safety issue: Yes ]
  • Change From Baseline in FEV1 [ Time Frame: Baseline through extension follow up Month 3 ] [ Designated as safety issue: Yes ]
  • Annual Rate of Change in FEV1 [ Time Frame: Week -2 through extension follow up Month 3 or end of study ] [ Designated as safety issue: Yes ]
  • Summary of ≥ 15 % Decliners in FEV1 [ Time Frame: Month 3 through extension follow up Month 3 ] [ Designated as safety issue: Yes ]
  • Annual Rate of Change in Carbon Monoxide Diffusion Capacity (DLco) [ Time Frame: Week -2 through extension follow up Month 3 or end of study ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Carbon Monoxide Diffusion Capacity (DLco) [ Time Frame: Baseline through extension follow up Month 3 ] [ Designated as safety issue: Yes ]
  • Summary of ≥ 20 % Decliners in DLco [ Time Frame: Month 3 through extension follow up Month 3 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Forced Vital Capacity (FVC) [ Time Frame: Week -3 through extension follow up Month 3 or end of study ] [ Designated as safety issue: Yes ]
  • Total Lung Capacity (TLC) [ Time Frame: Baseline through extension follow up Month 3 ] [ Designated as safety issue: Yes ]
  • Change From Baseline in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline through extension follow up Month 3 ] [ Designated as safety issue: No ]
  • Change From Baseline in Fasting Plasma Glucose (FPG) [ Time Frame: Baseline through extension follow up Month 3 ] [ Designated as safety issue: No ]
  • Change From Baseline in Body Weight [ Time Frame: Baseline through extension follow up Month 3 ] [ Designated as safety issue: No ]
  • Total Daily Long-acting Insulin Dose (Unadjusted for Body Weight) [ Time Frame: Month 3 through extension Month 36 ] [ Designated as safety issue: No ]
  • Total Daily Long-acting Insulin (Adjusted for Body Weight) [ Time Frame: Month 3 through extension Month 36 ] [ Designated as safety issue: No ]
  • Total Daily Short-acting Insulin Dose (Unadjusted for Body Weight) [ Time Frame: Month 3 through extension Month 36 ] [ Designated as safety issue: No ]
  • Total Daily Short-acting Insulin Dose (Adjusted for Body Weight) [ Time Frame: Month 3 through extension Month 36 ] [ Designated as safety issue: No ]
  • Lipid Panel: Total Cholesterol, High Density Lipoprotein, Low Density Lipoprotein, and Triglycerides [ Time Frame: Week -4 through Month 24 ] [ Designated as safety issue: No ]
  • Hypoglycemic Event Rates [ Time Frame: Month 1 through extension Month 36 ] [ Designated as safety issue: No ]
  • Severe Hypoglycemic Event Rates [ Time Frame: Month 1 through extension Month 36 ] [ Designated as safety issue: No ]
  • Cough Questionnaire [ Time Frame: Week 0 and if indicated through extension follow up Month 3 ] [ Designated as safety issue: No ]
  • Baseline Dyspnea Index (BDI) [ Time Frame: Week -1 ] [ Designated as safety issue: Yes ]
  • Transition Dyspnea Index (TDI) [ Time Frame: Week 4 through extension follow up Month 3 or end of study ] [ Designated as safety issue: Yes ]
  • High Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Within Normal Limits [ Time Frame: Baseline, M12, M24, Ext M6, Ext M18, Ext M36 ] [ Designated as safety issue: Yes ]
  • High Resolution Computerized Tomography (HRCT) Scan: Within Normal Limits (Yes or No) at Observation When Baseline HRCT Was Not Within Normal Limits [ Time Frame: Baseline, M12, M24, Ext M6, Ext M18, Ext M36 ] [ Designated as safety issue: Yes ]
  • Insulin Antibodies [ Time Frame: Baseline through extension Month 36 ] [ Designated as safety issue: Yes ]

Enrollment: 635
Study Start Date: June 2002
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Inhaled Insulin
Inhalable short-acting insulin
Drug: Inhaled Insulin
Inhaled insulin with dose adjusted according to premeal blood glucose
Other Name: Exubera
Active Comparator: Subcutaneous insulin Drug: Subcutaneous insulin
Subcutaneous insulin with dose adjusted according to premeal blood glucose

Detailed Description:

Pfizer announced in October 2007 that it would stop marketing Exubera. Nektar, the company from which Pfizer licensed Exubera, announced on April 9, 2008 that it had stopped its search for a new marketing partner. Accordingly, there will be no commercial availability of Exubera. As a result, study A2171029 was terminated on June 9, 2008. Neither safety nor efficacy reasons were the cause of the study termination.

  Eligibility

Ages Eligible for Study:   35 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Type 2 diabetes mellitus

Exclusion Criteria:

  • COPD
  • Asthma
  • Smoking Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00136916

  Hide Study Locations
Locations
United States, Arizona
Pfizer Investigational Site
Phoenix, Arizona, United States, 85016
Pfizer Investigational Site
Tucson, Arizona, United States, 85715
United States, California
Pfizer Investigational Site
Fresno, California, United States, 93720
Pfizer Investigational Site
Greenbrae, California, United States, 94904
Pfizer Investigational Site
Los Angeles, California, United States, 90073
Pfizer Investigational Site
Sacramento, California, United States, 95816
Pfizer Investigational Site
San Diego, California, United States, 92103
Pfizer Investigational Site
San Diego, California, United States, 92108
Pfizer Investigational Site
San Luis Obispo, California, United States, 93401
Pfizer Investigational Site
Tustin, California, United States, 92780
Pfizer Investigational Site
Walnut Creek, California, United States, 94598
United States, Colorado
Pfizer Investigational Site
Denver, Colorado, United States, 80209
United States, Connecticut
Pfizer Investigational Site
Hamden, Connecticut, United States, 06518
Pfizer Investigational Site
Madison, Connecticut, United States, 06443
Pfizer Investigational Site
New Britain, Connecticut, United States, 06050
Pfizer Investigational Site
Waterbury, Connecticut, United States, 06708
United States, Florida
Pfizer Investigational Site
Chiefland, Florida, United States, 32626
Pfizer Investigational Site
Clearwater, Florida, United States, 33761
Pfizer Investigational Site
Fort Myers, Florida, United States, 33901
Pfizer Investigational Site
Hollywood, Florida, United States, 33021
Pfizer Investigational Site
Miami, Florida, United States, 33156
Pfizer Investigational Site
Ocala, Florida, United States, 34471
Pfizer Investigational Site
Palm Harbor, Florida, United States, 34684
Pfizer Investigational Site
Tallahassee, Florida, United States, 32308
Pfizer Investigational Site
West Palm Beach, Florida, United States, 33401
United States, Hawaii
Pfizer Investigational Site
Honolulu, Hawaii, United States, 96814
Pfizer Investigational Site
Honolulu, Hawaii, United States, 96813
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States, 60607
Pfizer Investigational Site
Chicago, Illinois, United States, 60602
Pfizer Investigational Site
Chicago, Illinois, United States, 60610
Pfizer Investigational Site
Springfield, Illinois, United States, 62704
Pfizer Investigational Site
Wilmette, Illinois, United States, 60091
United States, Louisiana
Pfizer Investigational Site
New Orleans, Louisiana, United States, 70112
United States, Maryland
Pfizer Investigational Site
Bethesda, Maryland, United States, 20817
United States, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts, United States, 02215
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48106
Pfizer Investigational Site
Bloomfield Hills, Michigan, United States, 48302
Pfizer Investigational Site
Plymouth, Michigan, United States, 48170
Pfizer Investigational Site
Royal Oak, Michigan, United States, 48073
Pfizer Investigational Site
Southfield, Michigan, United States, 48034
United States, Missouri
Pfizer Investigational Site
Chesterfield, Missouri, United States, 63017
Pfizer Investigational Site
St. Louis, Missouri, United States, 63141
United States, Montana
Pfizer Investigational Site
Butte, Montana, United States, 59701
United States, Nebraska
Pfizer Investigational Site
Lincoln, Nebraska, United States, 68521
United States, Nevada
Pfizer Investigational Site
Henderson, Nevada, United States, 89014
United States, New Mexico
Pfizer Investigational Site
Albuquerque, New Mexico, United States, 87108
Pfizer Investigational Site
Albuquerque, New Mexico, United States, 87109
United States, New York
Pfizer Investigational Site
Mineola, New York, United States, 11501
Pfizer Investigational Site
New Hyde Park, New York, United States, 11042
Pfizer Investigational Site
Rochester, New York, United States, 14609
United States, North Carolina
Pfizer Investigational Site
Durham, North Carolina, United States, 27713
Pfizer Investigational Site
Winston-Salem, North Carolina, United States, 27103
United States, Ohio
Pfizer Investigational Site
Mansfield, Ohio, United States, 44903
United States, Oklahoma
Pfizer Investigational Site
Tulsa, Oklahoma, United States, 74104
United States, Rhode Island
Pfizer Investigational Site
Warwick, Rhode Island, United States, 02886
United States, Texas
Pfizer Investigational Site
Beaumont, Texas, United States, 77706
Pfizer Investigational Site
Beaumont, Texas, United States, 77701
Pfizer Investigational Site
Corpus Christi, Texas, United States, 78412
Pfizer Investigational Site
Corpus Christi, Texas, United States, 78411
Pfizer Investigational Site
Dallas, Texas, United States, 75231
Pfizer Investigational Site
Dallas, Texas, United States, 75230
Pfizer Investigational Site
Dallas, Texas, United States, 75246
Pfizer Investigational Site
Houston, Texas, United States, 77079
Pfizer Investigational Site
Irving, Texas, United States, 75061
Pfizer Investigational Site
San Antonio, Texas, United States, 78229
United States, Vermont
Pfizer Investigational Site
Burlington, Vermont, United States, 05401
United States, Virginia
Pfizer Investigational Site
Richmond, Virginia, United States, 23225
United States, Washington
Pfizer Investigational Site
Renton, Washington, United States, 98055
United States, Wisconsin
Pfizer Investigational Site
Milwaukee, Wisconsin, United States, 53209
Brazil
Pfizer Investigational Site
Porto Alegre, RS, Brazil, 90035-170
Pfizer Investigational Site
Sao Paulo, SP, Brazil, 01244-030
Canada, Alberta
Pfizer Investigational Site
Calgary, Alberta, Canada, T2T 5C7
Pfizer Investigational Site
Calgary, Alberta, Canada, T3B 0M3
Pfizer Investigational Site
Red Deer, Alberta, Canada, T4N 6V7
Canada, British Columbia
Pfizer Investigational Site
Victoria, British Columbia, Canada, V8R 1J8
Canada, Manitoba
Pfizer Investigational Site
Winnepeg, Manitoba, Canada, R3A 1R9
Pfizer Investigational Site
Winnipeg, Manitoba, Canada, R3E 3P4
Canada, Nova Scotia
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 2Y9
Pfizer Investigational Site
Halifax, Nova Scotia, Canada, B3H 1V7
Canada, Ontario
Pfizer Investigational Site
London, Ontario, Canada, N6A 4V2
Pfizer Investigational Site
Ottawa, Ontario, Canada, K1H 1A2
Pfizer Investigational Site
Toronto, Ontario, Canada, M4N-3M5
Pfizer Investigational Site
Toronto, Ontario, Canada, M5G 1X5
Canada, Quebec
Pfizer Investigational Site
Laval, Quebec, Canada, H7T 2P5
Pfizer Investigational Site
Montreal, Quebec, Canada, H3A 1A1
Pfizer Investigational Site
Montreal, Quebec, Canada, H1T 2M4
Canada, Saskatchewan
Pfizer Investigational Site
Saskatoon, Saskatchewan, Canada, S7N 0W8
Puerto Rico
Pfizer Investigational Site
Aguas Buenas, Puerto Rico, 00703
Pfizer Investigational Site
Anasco, Puerto Rico, 00610
Pfizer Investigational Site
Cabo Rojo, Puerto Rico, 00623
Pfizer Investigational Site
San Juan, Puerto Rico, 00909
Pfizer Investigational Site
San Juan, Puerto Rico, 00921
Sponsors and Collaborators
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by Pfizer

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc.
ClinicalTrials.gov Identifier: NCT00136916     History of Changes
Other Study ID Numbers: A2171029
Study First Received: August 25, 2005
Results First Received: December 10, 2009
Last Updated: February 12, 2010
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 28, 2014